Tetravalent dengue vaccine
AssigneeInternational Centre for Genetic Engineering and Biotechnology
InventorsNavin KHANNA, Viswanathan RAMASAMY
Life of this patent
Estimating the term…
Abstract
The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4 linked to the N-terminal of HBsAg.
Claims6
-9. (canceled)
A tetravalent dengue vaccine comprising a virus like particle (VLP) comprising:
- a) a recombinant polypeptide comprising an EDIII domain of each of Dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4, linked to N-terminal of an HBsAg polypeptide, as depicted below:
- EDIII-1 - - - EDIII-3 - - - EDIII-4 - - - EDIII-2 - - - HBsAg;
- wherein the dotted line is a linker;
- and
- wherein the amino acid sequence of the EDIII domains of each of Dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4 is SEQ ID NO's 1, 2, 3 and 4, respectively;
- and
- b) 4 units of an HBsAg polypeptide.
A method of eliciting neutralizing antibody titer against each of the four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4 in a subject in need thereof comprising administering to the subject the tetravalent dengue vaccine of claim 1.
A method of treating or preventing dengue virus infection comprising administering to a subject the tetravalent dengue vaccine of claim 1.
The tetravalent dengue virus vaccine of claim 1 for use in eliciting neutralizing antibody titer against each of the four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4.
The tetravalent dengue virus vaccine of claim 1 for use in treating or preventing dengue virus infection.
Dependencies are inferred from the claim text.